Elan Sells Back Frova Rights; Vernalis Plans Menstrual Migraine Filing In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Vernalis is seeking a new U.S. marketing partner for the triptan. Elan will use proceeds from the $55 mil. deal toward the Antegren launch.
You may also be interested in...
Endo To Boost Sales Force Following Frova In-Licensing Deal With Vernalis
The company will add about 70-80 reps to its existing sales force base of 230; detailing for the triptan will target specialty care physicians. Endo will make a $40 mil. milestone payment to Vernalis upon FDA approval for a menstrually associated migraine indication.
Endo To Boost Sales Force Following Frova In-Licensing Deal With Vernalis
The company will add about 70-80 reps to its existing sales force base of 230; detailing for the triptan will target specialty care physicians. Endo will make a $40 mil. milestone payment to Vernalis upon FDA approval for a menstrually associated migraine indication.
Eisai Acquires Elan's Zonegran; Will Detail With Aricept
Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.